AU · rank #2 · 2026-07-20
DIA
GPW · PLN · $1.52B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.240 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.38 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $204.28 | +19.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +9.02% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +79.3% |
| 52w high | $214.46 |
| Market cap (USD) | $1.52B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Diagnostyka S.A. operates Poland's leading nationwide medical diagnostics network, offering over 4,000 types of routine and specialized tests across more than 150 laboratories and 1,100 collection points [BIZ].
Rationale
The ~19.5% analyst upside is backed by strong cash generation, a high gross margin of 79.3%, and double-digit Q1 2026 consolidated revenue growth (+10.3% y/y standalone) [DEV, FIN].
Material risks
- 1Potential commoditization of routine laboratory tests and competitive pressure from hospital-based or independent labs could erode the company's volume growth and pricing power [RSK].
- 2Elevated valuation multiples (P/E of 22.44x and P/BV of 9.70x) leave the stock highly vulnerable to any growth deceleration or margin compression [FIN, RSK].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.